Brief: Cumberland Pharmaceuticals Receives FDA Orphan Drug And Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy
06/11/2024 22:24
Nov 6 (Reuters) - Cumberland Pharmaceuticals Inc
CPIX.O :
* CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND
RARE
PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE
MUSCULAR DYSTROPHY
Source text: ID:nPn4TwH93a
Further company coverage: CPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM